Who we are?

Pharmaseed is Israel’s largest GLP-certified pre-clinical and early clinical CRO specializing in translational and regenerative studies.

Pharmaseed is equipped for the execution of NCE studies, biologics and medical-devices as well as conducting and following through from the development stage until first-in-man trials. These studies include safety and efficacy evaluation in various animal models in addition to complementary in-vitro/ex-vivo models and on-site human anatomy services.

Pharmaseed’s expertise in preclinical studies lies mostly in the following areas:
Cardio/vascular, Immuno-Oncology, Stem cell and Cellular Therapeutics, Microbiome research, Infectious Diseases, and CNS.

Founded in 2003, Pharmaseed is a GLP-certified contract research organization (CRO) providing pre-clinical, early clinical and consulting services for medical device, biotechnology and pharmaceutical companies. Pharmaseed also provides pre-formulation services for small and medium-size start-up companies as well as companies in the idea and feasibility stages.

Pharmaseed’s experienced team forms an efficient organization whose global reach includes a network of sponsors from the U.S., Europe, Canada and Israel. This network has enabled Pharmaseed to establish JV programs with pharmaceutical companies and academia as well as a top-tier S.A.B./K.O.L. panel from multinational bio-pharma companies.

All our services are priced at a competitive rate in comparison to European and U.S.- based companies.

Why work with us?

Innovative technology requires an innovative CRO
Pharmaseed is Israel’s largest GLP - certified pre-clinical and early clinical CRO, specializing in translational projects of all stages, mastering the “end in mind” approach.
With over 20 years of experience, a professional team which includes over 13 PHD and postdoctoral level researchers who have held key positions within the life sciences industry, state of the art laboratory, in house vivarium, BL2 safety unit and a modern in vitro laboratory, we are conducting multidisciplinary, complex studies covering molecular, cellular and in vivo needs according to the highest ethical and regulatory standards.

During our 20 years of activity, we have learned how to adjust and balance creativity and flexibility, maintaining rigid ethics and quality demands.
Pharmaseed provides in depth knowledge and experience in planning and interpreting study results. We offer high end “one stop shop” R&D services, hence, multiplying the chances of transforming your product from a mere idea, to a real sustainable technology.

Safety & ADME

Toxicity studies investigate the safety profile of a candidate compound, as well as providing important information about the absorption, distribution, metabolism, and excretion (ADME) of the compound in the body. A candidate compound must be assessed in different kinds of non-clinical toxicity studies before it can be administered to the first human volunteer. Toxicology studies can be either single-dose or repeated-dose studies.
Whether your compound is an original small molecule or bioequivalent generic, injectable large molecule or biosimilar – our experts are true specialists.